| Share

Pheburane Listed on the Pharmaceutical Benefits Scheme



Pheburane will be funded from the 1st December 2019 for the treatment of Urea Cycle Disorders

Pheburane Listed on the Pharmaceutical Benefits Scheme


MELBOURNE, Australia, December 1st, 2019 – Orpharma Pty Ltd. and Lucane Pharma SA. are pleased to announce the listing of Pheburane on the Pharmaceutical Benefits Scheme (PBS). Pheburane will be funded from the 1st December 2019 for the treatment of Urea Cycle Disorders (UCDs).

 

Pheburane was approved by Australia’s TGA in May 2017 for the treatment of UCDs. Listing on the PBS will make the product readily available to all patients diagnosed with the condition. The Product Information can be accessed here. The Consumer Medicine Information can be accessed here.

 

Pheburane is an improved formulation of Sodium Phenylbutyrate, a standard treatment for UCD patients to remove ammonia. Sodium phenylbutyrate has a very strong bitter and salty taste which may compromise compliance to treatment, especially in children. Pheburane offers a formulation where the taste is completely masked.

 

PBS Prescribing Information

 

Max.Qty Packs

No. of Repeats

Prescribing code

Prescribers

3

5

11865L

Medical Practitioner

Nurse Practitioner

 

 

About Orpharma

Orpharma is an Australian pharmaceutical company focused on the supply of orphan, paediatric and emerging therapeutics. Orpharma is Australia’s first and only one stop shop for metabolic products supplying a range of low protein food, medical nutrition and medicines. Orpharma is collaborating with global leaders in biotechnology and pharmaceuticals to deliver therapies to patients in need. The company’s current product portfolio includes innovative medicines targeting rare metabolic diseases, cancer and anti-infectives. For more information about Orpharma visit www.orpharma.com

 

About Lucane Pharma

French Lucane Pharma S/A, Paris, incorporated in 2009 is part of Dutch based privately owned company Eurocept Pharmaceuticals Holding. The company specializes in the development and commercialization of medicinal products targeting rare disorders.

 

Its’ products will provide patients with a real improvement in the management of their disease: new products for diseases currently lacking effective treatment, improved formulations of existing products, new presentations fulfilling a specific need, existing products not available in most countries.